Eli Lilly (LLY) Operating Leases (2019)
Eli Lilly posted quarterly Operating Leases of $608.4 million for Q4 2019, down 0.51% on a QoQ basis from $611.5 million in Q3 2019.
Eli Lilly (LLY) has 1 years of Operating Leases data on file, last reported at $608.4 million in Q4 2019.
- For the quarter ending Q4 2019, Operating Leases changed N/A year-over-year to $608.4 million; the trailing twelve-month figure through Dec 2019 stood at $608.4 million (changed N/A YoY), and the FY2019 full-year result was $608.4 million, changed N/A from the prior year.
- Operating Leases for Q4 2019 stood at $608.4 million, down from $611.5 million in the prior quarter.
- Across five years, Operating Leases topped out at $621.9 million in Q1 2019 and bottomed at $503.3 million in Q2 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 608.40 Mn |
| Sep 30, 2019 | 611.50 Mn |
| Jun 30, 2019 | 503.30 Mn |
| Mar 31, 2019 | 621.90 Mn |